The stock has gained for seven of the previous 10 trading sessions. The company’s shares were also the biggest gainer on the Nifty Pharma index in intraday trade on Monday.
The stock has risen nearly 19% since the beginning of this month.
The company’s shares have risen over 56% since the beginning of the year and over 52% over the trailing 12-month period. The stock is 9% away from its 52-week high of ₹2,422.30.
The pharmaceutical company reported a consolidated net profit of ₹106 crore in the June quarter, compared with a ₹90 crore loss in the year-ago quarter. Revenue from operations rose 26% to ₹929 crore from ₹738 crore.
Its earnings before interest, taxes, depreciation and amortisation (EBITDA) increased to ₹192 crore from ₹72 crore a year earlier, while the EBITDA margin improved to 20.67% from 9.76%.
On June 1, Wockhardt’s shares had surged more than 19% intraday after the US Food and Drug Administration (USFDA) approved its antibiotic WCK 5222, marketed as Zaynich, for treating complicated urinary tract infections.
The approval made Zaynich the first antibiotic discovered and developed in India to receive US regulatory clearance. The drug had received Fast Track and Qualified Infectious Disease Product designations, while Wockhardt filed its New Drug Application in October 2025 and secured approval in less than a year.
According to the latest shareholding data, 49.08% of the company’s shares were held by promoters, while 50.92% comprised public shareholding. Foreign institutional investors held only 0.01% of the company’s shares.
Shares of Wockhardt gained 7.1% to hit an intraday high of ₹2,236 apiece on Monday. The stock was up 5% at 2,192 apiece at 1.20 pm.
